Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Dr. Tang Dajie, founder and CEO of investment vehicle Triwise Capital, discusses the numerous investment opportunities in Shenzhen’s life sciences sector and the city’s unique geographical and economic positioning. Dr.…
Tian Yaolin, CEO of Shenzhen Govita Medical Laboratory, shares the exciting story of Govita’s start-up in the past two years; their robust and innovative business model centered on healthcare management…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal…
Many of your counterparts have spoken about the unique operational and strategic challenges China poses to their organizations. How does PAREXEL adapt itself to compete in China, and how does…
Every “sea turtle” has a different story. What’s yours, and how did you come to found Wincon? I am a “sea turtle” just like other Chinese returnees. I’m a medical doctor…
You are the CEO of GCP CMIC ClinPlus in addition to R&G PharmaStudies, and before that you headed a number of companies as well. Could you introduce yourself and all…
We’re meeting you just after a conference where you were a keynote speaker. Could you share with us some of your insights from the day’s events? The conference was a…
We last met with you as the head of Zuellig in 2009. Obviously, a lot has changed since then; from both a sector and corporate point of view, what have…
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Among Big Pharma, Sanofi has a track record of placing a lot of faith in emerging markets – with local production, a large product portfolio, and decades of experience. As…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr. Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, Neucardin®, which has been shown…
See our Cookie Privacy Policy Here
